In recent years, cancer therapy blocking the PD-1/PD-L1 coinhibitory pathway has demonstrated reactivation of T cell immunity, leading to remarkable survival benefits in patients with cancer of various types [25–28]. The gene discussed is PDCD1; the disease is cancer.